PAR-1 expression on ALL cells represents an important adverse prognostic factor and therefore its expression should be routinely investigated for better prognostic assessment of ALL patients at diagnosis and should be taken in consideration in designing future therapeutic strategies based on patient- specific risk factors. The gene discussed is F2R; the disease is acute lymphoblastic leukemia.